TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Plasma Concentration of FVIII:C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with infraorbital nerve involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of venous thromboembolic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dietary Vegetable Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary Nutrient Intake (vitamins & minerals)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Recruited in a 6-Month Time-frame
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants That Stay in Study for Duration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants That Attend All Intervention Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of Scores from questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Percent Change of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Induction of antigen-specific immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ventilation Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change of 6 Minute Walking Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of voriconazole antifungal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 3-month modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Deoxycytidine Kinase (dCK) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with Major Adverse Kidney Events within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Net change of the Patients Perception of Bladder Condition (PPBC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: American College of Rheumatology Combined Response Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients re-intubated within 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite endpoint of deep vein thrombosis, non-fatal pulmonary embolism, and death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Treatment-emergent bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture positive
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participant deaths
Endpoint domain: Mortality/survival
Primary endpoint: Visual analogue scale for pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enteral intake (ml/kg/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: number of mature oocytes (MII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change From Baseline in Brain Amyloid Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of treatment emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: clinical laboratory assessments of plasma PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of malaria parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Salivary vitamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma vitamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Physician Global Assessments for Active Skin Manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Patient Global Assessments for Active Skin Manifestations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Dermatology Life Quality Index (DLQI) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With at Least One Treatment-related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Total Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-related Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Accurate Vesical Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Slit Lamp Examination > Grade 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Approximal Plaque Index (API)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingiva Sulcus Bleeding Index (SBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries and Initial Caries Index: decayed, missing, filled teeth (idmft)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA-Progression free survival (PSA-PFS)
Endpoint domain: Mortality/survival
Primary endpoint: motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CERAD Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients achieving a response or complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Good neurological survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants Achieving sPGA 0/1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of the LCS® Complete AP Glide knee prosthesis
Endpoint domain: Mortality/survival
Primary endpoint: Plasma cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak plasma concentration (Cmax) of amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankylosing Spondylitis Response (ASAS 20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal re-attachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 years disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Area of punctuate hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration(last) and Cmax of CKD-501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without treatment related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Breathing Discomfort (Dyspnea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: BOLD activation during A1 phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3 month hematological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drain position on the tympanic membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: changes in intrahepatic fat concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Endpoint domain: Mortality/survival
Primary endpoint: Change in Level of Adherence (Objective Measure)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Level of Adherence (Parent- and Patient-Reported): MSTAQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Level of Adherence (Parent- and Patient-Reported): Morisky
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Level of Adherence (Parent- and Patient-Reported): Parental Involvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Triglyceride composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of patient with grade 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reflux esophagitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric Emptying Half-time (t1/2) at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of cardio-toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diagnosis of inflammatory rheumatic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prognostication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment effectiveness and tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of PRO-118 ophthalmic solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for anthocyanin blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incremental area under the curve for anthocyanin blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in harmony
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Antibody titres to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major adverse cardiovascular events (MACE) reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total morphine requirement in 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants showing seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physician Global Assessment of Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevention of ischemic hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Survival of burn patients
Endpoint domain: Mortality/survival
Primary endpoint: Safety of the AP Device
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of days walking 7000 steps or more
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Transient Ischemic Attack
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IgG Trough Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Behavioral Performance on the Probabilistic Stimulus Selection Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Performance on the Instrumental Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude mortality estimation
Endpoint domain: Mortality/survival
Primary endpoint: Attributable mortality by VAP
Endpoint domain: Mortality/survival
Primary endpoint: Rate of progression to multiple organ failure and septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression to multiple organ failure and septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of the interaction with the robot
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Usability of the robot
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sociability with the robot
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Efficacy of Bemcentinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of serum 2HG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemodynamic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 36-Month Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Peak Vertical Force on Affected Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who change their risk profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of cases of shigellosis and ETEC-associated diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mindfulness Resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Baseline Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of Baseline Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Baseline Salivary cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of CSDH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Neuropathic Pain Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eye comfort index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: relative risk of child being up to date with all age-appropriate vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Seroconverted to Wild Type JE Virus Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Solicited Local Injection Site and Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with uncontrolled asthma post omalizumab treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with excessive SABA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with exacerbations requiring IP visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow cytometry assay of biomarkers (CD64, CD169)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anti-dyskinetic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of voluntary drug intoxications
Endpoint domain: Adverse events/effects
Primary endpoint: BV/TV ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steroid metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of cesarean deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sepsis SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of chemotherapy induced-peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of administration of CTLs
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of muscular contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood levels of oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary levels of oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: amiloride plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Postoperative Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of MRI Scan-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of DM scan vs iTero scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life of primary caregiver
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnosis of acute heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patients needing revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary Outcome Measure With iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete recovery in stress pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum kynurenine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kynurenic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole brain gray matter and frontal gray matter cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medial prefrontal cortex glutamate levels using magnetic resonance spectroscopy (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medial prefrontal cortex glutathione metabolite levels using magnetic resonance spectroscopy (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of cancer specific antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Extremity Functional Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in First Step Pain in the Morning (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Intensity (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Time to need for mechanical ventilation (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum tolerated dose (MTD) or biologically effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety defined by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of children that tolerate the full challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of underage alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glycated hemoglobin (HbA1c)%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Comfort Score (Senofilcon A Lens)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Comfort Score (Galyfilcon A Lens)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Comfort Score (Etafilcon A Lens)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall tremor reduction proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes